Researchers have been excited about the medication , a innovative dual agonist showing significant results in initial trials for body reduction . It works by impacting both pathways : GLP-1 and GIP, that , when stimulated, assist control appetite and enhance calorie burn. Initial findings suggest substantial size loss and likely improvements for pe